Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | SMYD3 | Q9H7B4 | 12/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.46 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265042 | 1.00 | AHR (0.50) | AHREPHX2SMYD3GRIA1CACNG8 | |
| SCHEMBL688076 | 0.82 | EPHX2 (0.56) | AHREPHX2SMYD3HDAC3GAA | |
| SCHEMBL1519697 | 0.81 | SMYD3 (0.50) | AHREPHX2SMYD3GRIA1CACNG8 | |
| SCHEMBL1519694 | 0.81 | SMYD3 (0.50) | AHREPHX2SMYD3GRIA1CACNG8 | |
| SCHEMBL3660152 | 0.81 | AHR (0.53) | AHREPHX2SMYD3GRIA1CACNG8 | |
| SCHEMBL688890 | 0.77 | TDP2 (0.61) | AHREPHX2SMYD3PDE3BPDE3A | |
| SCHEMBL29567045 | 0.76 | SMYD3 (0.57) | AHREPHX2SMYD3GRIA1CACNG8 | |
| SCHEMBL3190474 | 0.76 | SMYD3 (0.57) | AHREPHX2SMYD3GRIA1CACNG8 | |
| SCHEMBL12673437 | 0.75 | EPHX2 (0.52) | AHREPHX2SMYD3HDAC3 | |
| SCHEMBL688478 | 0.75 | CRBN (0.58) | AHREPHX2SMYD3HDAC3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134004-B2 | Substituted N-bicyclicalkyl bicycliccarboxyamide compounds | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | OPRL1, CNR1, TRPV1 | AHR 750/4885EPHX2 3146/4885SMYD3 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.